ConvaTec Group plc ((GB:CTEC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec Group plc is conducting a study titled ‘SCOPE – Single-Point Classification Observational Peristomal Evaluation’ to assess the interrater reliability of SACS 2.0 for evaluating peristomal skin health in ostomates. This observational study aims to create a comprehensive dataset of ostomy images, comparing digital evaluations with traditional in-person assessments, which could significantly enhance clinical practices and patient outcomes.
The study involves no direct interventions but focuses on collecting and analyzing images from subjects with ileostomy, colostomy, and urostomy to improve the assessment of peristomal skin conditions.
The study employs a case-control observational model with a prospective time perspective. It is designed to gather data without allocating specific interventions, focusing on observational insights.
Key dates for the study include the start date on September 24, 2024, with the latest update submitted on May 16, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This study update could positively impact ConvaTec’s stock performance by demonstrating the company’s commitment to innovation in ostomy care. As the study progresses, it may influence investor sentiment and position ConvaTec favorably against competitors in the medical device industry.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.